Trimethylammonium

Trimethylammonium

SCHEMBL136535

CCC=C(C)C(=O)O.CN(C)C.CN(C)C.Cl

nearest known ligand 0.35

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Trimethylammonium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
PTGS1 known ✓ P23219 1/20 0.31
GRIK1 P39086 1/20 0.35
GRIK2 Q13002 1/20 0.35
CD81 P60033 1/20 0.32
AKR1C3 P42330 1/20 0.31
EP300 Q09472 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trimethylammonium SCHEMBL11169491 1.00 GRIK1 (0.35) GRIK1GRIK2CD81PTGS1AKR1C3
Trimethylammonium SCHEMBL136534 1.00 GRIK1 (0.35) GRIK1GRIK2CD81PTGS1AKR1C3
Trimethylammonium SCHEMBL1469277 0.98 GRIK1 (0.36) GRIK1GRIK2CD81PTGS1AKR1C3
Trimethylammonium SCHEMBL679439 0.98 GRIK1 (0.36) GRIK1GRIK2CD81PTGS1AKR1C3
Trimethylammonium SCHEMBL27571825 0.95 GRIK1 (0.35) GRIK1GRIK2CD81PTGS1AKR1C3
Hydrochloric Acid SCHEMBL2564983 0.93
SCHEMBL17819 0.90
SCHEMBL17817 0.90
SCHEMBL5716965 0.90
N,N-Dimethylethanaminium SCHEMBL11902174 0.88 GRIK1 (0.34) GRIK1GRIK2CD81PTGS1AKR1C3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060013785-A1 Hairstyling gels with light protective action for skin and hair WELLA AG (DE) 2006-01-19 US claimed
CN-112739446-A Monovalent selective cation exchange membranes 懿华水处理技术有限责任公司 2021-04-30 CN disclosed
US-20170224604-A1 CATIONIC/CATIONOGENIC COMB COPOLYMER COMPOSITIONS AND PERSONAL CARE PRODUCTS CONTAINING THE SAME EVONIK DEGUSSA GMBH (DE) 2017-08-10 US disclosed
US-9561452-B2 Process and apparatus for treating drilling fluid ZEIDLER H UDO (CA) 2017-02-07 US disclosed
US-20150336030-A1 PROCESS AND APPARATUS FOR TREATING DRILLING FLUID ZEIDLER H UDO (CA) 2015-11-26 US disclosed
EP-2558510-B1 CATIONIC/CATIONOGENIC COMB COPOLYMER COMPOSITIONS AND PERSONAL CARE PRODUCTS CONTAINING THE SAME AIR PROD & CHEM (US) 2015-05-20 EP disclosed
WO-2014127477-A1 PROCESS AND APPARATUS FOR TREATING DRILLING FLUID ZEIDLER H UDO (CA) 2014-08-28 WO disclosed
US-20140220704-A1 ARTICLES COMPRISING TEMPLATED CROSSLINKED POLYMER FILMS FOR ELECTRONIC DETECTION OF NITROAROMATIC EXPLOSIVES THE JOHNS HOPKINS UNIVERSITY (US) 2014-08-07 US disclosed
WO-2013066456-A2 ARTICLES COMPRISING TEMPLATED CROSSLINKED POLYMER FILMS FOR ELECTRONIC DETECTION OF NITROAROMATIC EXPLOSIVES THE JOHNS HOPKINS UNIVERSITY (US) 2013-05-10 WO disclosed
US-20120184044-A1 MOLECULARLY-IMPRINTED POLYMERIC MATERIALS FOR VISUAL DETECTION OF EXPLOSIVES RAPTOR DETECTION, INC. (US) 2012-07-19 US disclosed
EP-0706399-A4 COMPOSITIONS AND PROCESS FOR REMOVING BILE SALTS GELTEX PHARMA INC (US) 1998-08-12 EP disclosed
EP-0706399-A1 COMPOSITIONS AND PROCESS FOR REMOVING BILE SALTS GELTEX PHARMACEUTICALS, INC. (US) 1996-04-17 EP disclosed
WO-1994027620-A1 COMPOSITIONS AND PROCESS FOR REMOVING BILE SALTS GELTEX PHARMACEUTICALS, INC. (US) 1994-12-08 WO disclosed
US-5316772-A Bilayered oral pharmaceutical composition with pH dependent release SOLVAY & CIE, S.A. (SOCIETE ANONYME) (BE) 1994-05-31 US disclosed
WO-1992011001-A1 ORAL PHARMACEUTICAL COMPOSITION SOLVAY (SOCIETE ANONYME) (BE) 1992-07-09 WO disclosed
EP-0192183-A2 Weakly cross-linked polymers or copolymers in the form of particles and quickly swellable in water, method for making them and their use in hygienic articles RÖHM GMBH (DE) 1986-08-27 EP disclosed
US-4367297-A Water-soluble poly(meth)acrylic acid derivatives gels and their manufacture CHEMISCHE FABRIK STOCKHAUSEN GMBH (DE) 1983-01-04 US disclosed
US-4217209-A Process for removing heavy metal sulphides from aqueous systems BAYER AKTIENGESELLSCHAFT (DE) 1980-08-12 US disclosed
US-4208309-A ACRYLAMIDE POLYMERS ROHM GMBH (DE) 1980-06-17 US disclosed
US-4190713-A CARRIERS FOR BIOLOGICALLY ACTIVE MATERIALS ROHM GMBH (DE) 1980-02-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170224604-A1 CATIONIC/CATIONOGENIC COMB COPOLYMER COMPOSITIONS AND PERSONAL CARE PRODUCTS CONTAINING THE SAME C9, CUTA, ZYX PTGS1 3205/4885GRIK1 1703/4885GRIK2 2420/4885
US-20060013785-A1 Hairstyling gels with light protective action for skin and hair SUCLG1, CUTA, MTCL3 PTGS1 1208/4885GRIK1 1978/4885GRIK2 2189/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.